Stockscreener 앱 받기
0.42
15.98%
-0.0799
시간 외 거래:
.43
0.01
+2.38%
전일 마감가:
$0.4999
열려 있는:
$0.5011
하루 거래량:
934.56K
Relative Volume:
6.29
시가총액:
$7.73M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-0.3555
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-22.08%
1개월 성능:
-77.42%
6개월 성능:
-86.67%
1년 성능:
-91.76%
1일 변동 폭
$0.32
$0.5011
1주일 범위
$0.32
$0.55
52주 변동 폭
$0.32
$5.275
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.42 | 8.23M | 0 | -16.26M | -13.50M | -1.1814 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Intensity Therapeutics Reports Q1 2025 Financial Results - TipRanks
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow
INTS Faces Challenges Yet Advances in Key Cancer Programs | INTS Stock News - GuruFocus
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Health Beat: Muscle loss and cognitive function - WFMZ.com
International Hummus Day arrives with a surge in plant-based picks - WFMZ.com
Curious? Healthy Brain Aging Might Depend On It - WFMZ.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Reg - GuruFocus
Intensity Therapeutics (INTS) Expands Cancer Trial to France | I - GuruFocus
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - Yahoo Finance
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Offerings News Live Feed - Stock Titan
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com
Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com
Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX
In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX
Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister
Intensity Therapeutics plunges on $2.35M public offering - MSN
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus
Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - Nasdaq
Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial - Nature
Intensity Therapeutics Inc (INTS)’s stock performance: a year in review - uspostnews.com
Intensity Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
INTS stock touches 52-week low at $1.49 amid market challenges - Investing.com Australia
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Intensity Therapeutics Highlights Cancer Treatment Progress - TipRanks
Is RollsRoyce (RYCEY) Stock Outpacing Its Aerospace Peers This Year? - Yahoo Finance
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why ArcelorMittal (MT) is a Top Value Stock for the Long-Term - Yahoo Finance
Tesla Delays Launch of Cheaper, Stripped-Down Version of Model Y in US - Yahoo Finance
The Zacks Analyst Blog Highlights Affirm, StoneCo, ACI Worldwide, Coinbase Global and OppFi - Yahoo Finance
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - Quantisnow
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Yahoo Finance
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of OD - American Heart Association Journals
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):